Literature DB >> 16308873

Rapid and direct measurement of free concentrations of highly protein-bound fluoxetine and its metabolite norfluoxetine in plasma.

Bin Guo1, Chuan Li, Guangji Wang, Laishun Chen.   

Abstract

Fluoxetine (F) and its active N-demethylated metabolite, norfluoxetine (NF), are selective serotonin re-uptake inhibitors that bind extensively to plasma proteins. Development and validation of a novel method for measuring free concentrations of F and NF in plasma are reported here. The plasma filtrate was prepared by a high-speed short-duration ultrafiltration (UF) and then submitted directly to a short-column liquid chromatography/tandem mass spectrometric (LC/MS/MS) assay. There was no significant matrix effect on the analysis, and non-specific binding of the analytes to the UF devices was negligible. For validation of the method, the recovery of the free analytes was compared to that from an optimized equilibrium dialysis method, and analyte stability was examined under conditions mimicking the sample storage, handling, and analysis procedures. The linearity range was 0.37-12 ng/mL for F and NF; the within-run and between-run relative standard deviations were less than 11.9%, and accuracies across the assay range were 100 +/- 10.3%. This new method was then further validated in a pharmacokinetic (PK) study in beagle dogs receiving a single oral dose of fluoxetine hydrochloride. The integrity of the resulting PK data of free F and NF was absolute. The PK data indicate that the novel method is accurate and reliable. To our knowledge this is the first report describing a rapid and reliable method for direct measurement of free concentrations of F and NF in plasma, which will be useful for clinical pharmacokinetic/pharmacodynamic studies of F. Furthermore, the strategies described herein may be applied to the development and validation of methods for measuring the free concentrations of other drugs in plasma. (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16308873     DOI: 10.1002/rcm.2265

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  16 in total

1.  Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.

Authors:  Chen-Chun Zhong; Feng Chen; Jun-Ling Yang; Wei-Wei Jia; Li Li; Chen Cheng; Fei-Fei Du; Su-Ping Zhang; Cheng-Ying Xie; Na-Ting Zhang; Olajide E Olaleye; Feng-Qing Wang; Fang Xu; Li-Guang Lou; Dong-Ying Chen; Wei Niu; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

2.  Systemic and cerebral exposure to and pharmacokinetics of flavonols and terpene lactones after dosing standardized Ginkgo biloba leaf extracts to rats via different routes of administration.

Authors:  Feng Chen; Li Li; Fang Xu; Yan Sun; Feifei Du; Xutao Ma; Chenchun Zhong; Xiuxue Li; Fengqing Wang; Nating Zhang; Chuan Li
Journal:  Br J Pharmacol       Date:  2013-09       Impact factor: 8.739

3.  Pharmacokinetic evaluation of the anticancer prodrug simmitecan in different experimental animals.

Authors:  Zhe-yi Hu; Xiu-xue Li; Fei-fei Du; Jun-ling Yang; Wei Niu; Fang Xu; Feng-qing Wang; Chuan Li; Yan Sun
Journal:  Acta Pharmacol Sin       Date:  2013-09-23       Impact factor: 6.150

4.  Intravenous formulation of Panax notoginseng root extract: human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions.

Authors:  Salisa Pintusophon; Wei Niu; Xiao-Na Duan; Olajide E Olaleye; Yu-Hong Huang; Feng-Qing Wang; Yan-Fen Li; Jun-Ling Yang; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2019-07-29       Impact factor: 6.150

5.  Human pharmacokinetics of ginkgo terpene lactones and impact of carboxylation in blood on their platelet-activating factor antagonistic activity.

Authors:  Xin-Wei Liu; Jun-Ling Yang; Wei Niu; Wei-Wei Jia; Olajide E Olaleye; Qi Wen; Xiao-Na Duan; Yü-Hong Huang; Feng-Qing Wang; Fei-Fei Du; Chen-Chun Zhong; Yan-Fen Li; Fang Xu; Qi Gao; Li Li; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-07-27       Impact factor: 6.150

6.  Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb-drug interactions on OATP1B3.

Authors:  Rongrong Jiang; Jiajia Dong; Xiuxue Li; Feifei Du; Weiwei Jia; Fang Xu; Fengqing Wang; Junling Yang; Wei Niu; Chuan Li
Journal:  Br J Pharmacol       Date:  2015-01-20       Impact factor: 8.739

7.  Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: potential joint precipitants of drug interactions.

Authors:  Olajide E Olaleye; Wei Niu; Fei-Fei Du; Feng-Qing Wang; Fang Xu; Salisa Pintusophon; Jun-Lan Lu; Jun-Ling Yang; Chuan Li
Journal:  Acta Pharmacol Sin       Date:  2018-10-16       Impact factor: 6.150

8.  Glycyrrhizin has a high likelihood to be a victim of drug-drug interactions mediated by hepatic organic anion-transporting polypeptide 1B1/1B3.

Authors:  Jiajia Dong; Olajide E Olaleye; Rongrong Jiang; Jing Li; Chuang Lu; Feifei Du; Fang Xu; Junling Yang; Fengqing Wang; Weiwei Jia; Chuan Li
Journal:  Br J Pharmacol       Date:  2018-07-23       Impact factor: 8.739

Review 9.  High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites.

Authors:  M Holcapek; L Kolárová; M Nobilis
Journal:  Anal Bioanal Chem       Date:  2008-03-15       Impact factor: 4.142

10.  Oral bioavailability and brain penetration of (-)-stepholidine, a tetrahydroprotoberberine agonist at dopamine D(1) and antagonist at D(2) receptors, in rats.

Authors:  Yan Sun; Jieyu Dai; Zheyi Hu; Feifei Du; Wei Niu; Fengqing Wang; Fei Liu; Guozhang Jin; Chuan Li
Journal:  Br J Pharmacol       Date:  2009-09-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.